The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
Moderna’s CEO, Stéphane Bancel, expressed the company’s commitment to protecting older adults from RSV-related diseases and their intention to supply the vaccine from their Melbourne facility.
vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older. 1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in ...
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian ...
The decision by the TGA was influenced by the positive outcomes from the Phase 3 clinical trial, ConquerRSV, which involved around 37,000 adults aged 60 and above across 22 countries. The vaccine ...
Zacks Investment Research on MSN2d
PFE Secures EU Nod for Expanded Use of RSV Vaccine AbrysvoPfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback